3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (4th Edition), 2022-2035
The 3D cell culture market is expected to reach USD 1.2 billion by 2022 anticipated to grow at a CAGR of 16.7% during the forecast period 2022-2035.
For a long time, animal testing has been a primary method in biomedical research due to the similarities animals share with humans in genetics, anatomy, and physiology. Mice, in particular, share approximately 80% of their genome with humans, making them valuable in various studies. However, concerns about animal welfare have led to the establishment of the 3Rs principle—Replacement, Reduction, and Refinement—to minimize animal use in research. Since 1985, this initiative has reduced animal testing by 50% by 2018. Breeding and housing animals for research purposes are expensive and require skilled labor. Moreover, differences in morphology and physiology between animal cell cultures and cells cultured in monolayers limit the faithful replication of the natural in vivo environment. To overcome these challenges, there's a growing trend towards transitioning from animal-based testing to 3D cell models. Advances in biotechnology and materials science have enabled the creation of various 3D cell culture systems, proving invaluable in cancer research, drug discovery, and tissue engineering. Over 140 companies now offer these systems in scaffold-based, scaffold-free, and 3D bioreactor formats. These systems simulate tissue microenvironments better, enhance cell interactions, accurately assess drug toxicity and cellular responses, and enable co-culture of multiple cell types. Complex 3D cell models are becoming viable replacements for animal models, providing reproducible results and serving as more effective in vivo models across various applications. This shift has drawn considerable attention from venture capital firms and investors, driving research into formats like organoids and organ-on-a-chip technology. Collaborations and scientific literature on 3D cell culture systems, bioreactors, and cell culture products are increasing, indicating growing interest and progress in this field. The ongoing innovation and transition from traditional 2D cell cultures and animal testing to 3D cell models are expected to significantly boost the 3D cell culture industry in the coming years.
Report Coverage
For a long time, animal testing has been a primary method in biomedical research due to the similarities animals share with humans in genetics, anatomy, and physiology. Mice, in particular, share approximately 80% of their genome with humans, making them valuable in various studies. However, concerns about animal welfare have led to the establishment of the 3Rs principle—Replacement, Reduction, and Refinement—to minimize animal use in research. Since 1985, this initiative has reduced animal testing by 50% by 2018. Breeding and housing animals for research purposes are expensive and require skilled labor. Moreover, differences in morphology and physiology between animal cell cultures and cells cultured in monolayers limit the faithful replication of the natural in vivo environment. To overcome these challenges, there's a growing trend towards transitioning from animal-based testing to 3D cell models. Advances in biotechnology and materials science have enabled the creation of various 3D cell culture systems, proving invaluable in cancer research, drug discovery, and tissue engineering. Over 140 companies now offer these systems in scaffold-based, scaffold-free, and 3D bioreactor formats. These systems simulate tissue microenvironments better, enhance cell interactions, accurately assess drug toxicity and cellular responses, and enable co-culture of multiple cell types. Complex 3D cell models are becoming viable replacements for animal models, providing reproducible results and serving as more effective in vivo models across various applications. This shift has drawn considerable attention from venture capital firms and investors, driving research into formats like organoids and organ-on-a-chip technology. Collaborations and scientific literature on 3D cell culture systems, bioreactors, and cell culture products are increasing, indicating growing interest and progress in this field. The ongoing innovation and transition from traditional 2D cell cultures and animal testing to 3D cell models are expected to significantly boost the 3D cell culture industry in the coming years.
Report Coverage
- The report conducts an analysis of the 3D cell culture market based on scaffold format, products, application areas, purpose, and key geographical regions
- It evaluates factors influencing market growth such as drivers, restraints, opportunities, and challenges.
- The report examines potential advantages and barriers within the market and provides insights into the competitive landscape for top market players.
- Revenue forecasts for market segments are provided concerning four major regions.
- A comprehensive analysis categorizes 3D cell culture systems into scaffold-based systems (including hydrogels/ECMs, solid scaffolds, micropatterned surfaces, and microcarriers), scaffold-free systems (comprising attachment-resistant surfaces, suspension systems, and microfluidic systems), and 3D bioreactors.
- An extensive review of fabrication techniques used for creating 3D matrices and scaffolds is conducted, highlighting materials, fabrication processes, merits, drawbacks, and diverse applications across different methods.
- A thorough examination of companies offering varied 3D cell culture systems includes parameters such as establishment year, employee base, global presence, cell culture format, product types, services, and associated reagents/consumables.
- Detailed evaluations of scaffold-based and scaffold-free products consider developmental status, product types, sources, materials used, and profiles of companies involved in their development.
- A comprehensive analysis of 3D bioreactors includes types, developmental status, working volume, scale of operation, manufacturing processes, application areas, and companies involved.
- Key application areas like cancer research, drug discovery, toxicology, stem cell research, tissue engineering, and regenerative medicine utilizing various 3D cell culture products are extensively reviewed.
- Elaborate profiles of leading companies engaged in scaffold-based, scaffold-free cell culture systems, and 3D bioreactors are provided, including company overview, financial details (if available), product portfolio, recent developments, and future outlook.
- Analysis of investments made (2016-2022) in small and mid-sized companies engaged in 3D cell culture product development across various financing stages is included.
- In-depth analysis of partnerships established since 2015 related to 3D cell culture products considering agreement types, cell culture formats, product types, and active players is conducted.
- A thorough examination of patents filed/granted (2016-2021) and scientific articles published (since 2019) related to 3D cell culture products considering focus areas, contributors, and geographic distribution is provided.
- Detailed assessment of 3D bioreactor competitiveness is conducted, considering factors such as supplier power, key features, supported molecules, cell cultures, and application areas.
- A case study on 3D cell culture products for organoids and organ-on-chips, covering developmental status, application areas, and developer company details is presented.
- Insights from an industry-wide survey featuring inputs from experts involved in 3D cell culture product development across various aspects like product focus, development status, fabrication methods, application areas, services offered, and market opportunities are analyzed.
- 3D Biotek
- Advanced BioMatrix
- Alphabioregen
- Corning Life Sciences
- REPROCELL
- CN Bio Innovations
- Emulate
- InSphero
- MIMETAS
- TissUse
- BISS TGT
- Celartia
- Cell Culture
- EBERS
- Flexcell International
- PBS Biotech
- Synthecon
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Cell Cultures
3.2.1. Primary Cell Cultures
3.2.2. Cell Lines
3.3. Morphology of Cells in Culture
3.4. 2D Cell Cultures vs 3D Cell Cultures
3.5. Overview of 3D Cell Culturing
3.5.1. Components of the Extracellular Matrix (ECM)
3.5.2. In Vitro Cell Culturing
3.5.3. Selection of Culture Format
3.6. Establishment and Maintenance of Cell Cultures
3.6.1. Isolating Cells from Tissues
3.6.2. Maintaining Cells in Culture
3.6.3. Sub-Culturing / Passaging
3.6.4. Cryogenic Storage
3.7. Requirements for Maintaining Healthy Cell Cultures
3.7.1. Safety Guidelines in a Cell Culture Facility
3.7.2. Cell Culture Health and Optimal Conditions for Growth
3.7.3. Cross Contamination in Cell Cultures
3.7.4. Methods to Prevent Contamination
3.8. Applications of 3D Cell Culture Systems
3.8.1. Model Systems
3.8.2. Drug Discovery and Preclinical Research
3.8.3. Cancer Research
3.8.4. Virology Research
3.8.5. Genetic Engineering and Gene Therapy Research
3.9. Advantages and Limitations of 3D Cell Culture Systems
3.10. Future Perspectives
4. CLASSIFICATION OF 3D CELL CULTURE SYSTEMS
4.1. 3D Cell Culture Classification
4.2. Scaffold Based 3D Cell Cultures
4.2.1. Hydrogels / ECM Analogs
4.2.2. Solid Scaffolds
4.2.3. Micropatterned Surfaces
4.2.4. Microcarriers
4.3. Scaffold Free 3D Cell Cultures
4.3.1. Attachment Resistant Surfaces
4.3.2. Suspension Culture Systems
4.3.2.1. Hanging Drop Plates
4.3.2.2. Magnetic Levitation and 3D Bioprinting
4.3.3. Microfluidic Surfaces and Organs-on-Chips
4.3.4. 3D Bioreactors
4.4. Organoids
5. FABRICATION OF 3D MATRICES AND SCAFFOLDS
5.1. Chapter Overview
5.2. Methods for Fabricating Porous Scaffolds
5.2.1. Particulate Leaching
5.2.2. Solvent Casting
5.2.3. Emulsion Templating
5.2.4. Gas Foaming
5.2.5. Melt Molding
5.2.6. Microsphere Sintering
5.3. Methods for Fabricating Fibrous Scaffolds
5.3.1. Electrospinning
5.3.2. Phase Separation
5.3.3. Self-Assembly
5.3.4. Fiber Mesh and Fiber Bonding
5.4. Methods for Fabricating Hydrogels
5.4.1. Gelation
5.4.2. Solvent Casting and Particulate Leaching
5.4.3. Gas Foaming
5.4.4. Freeze Drying
5.4.5. Co-polymerization / Crosslinking
5.4.6. Microfluidics
5.5. Methods for Fabricating Custom Scaffolds
5.5.1. Stereo-Lithography
5.5.2. 3D Bioprinting and Selective Laser Sintering (SLS)
5.5.3. Fused Deposition Modeling
5.5.4. Membrane Lamination
5.5.5. Rapid Prototyping / Solid Free-Form Technique
5.6. Methods for Fabricating Microspheres
5.6.1. Solvent Evaporation
5.6.2. Single and Double Emulsification
5.6.3. Particle Aggregation
5.7. Methods for Fabricating Native Scaffolds
5.7.1. Decellularization
6. 3D CELL CULTURE SYSTEMS: DEVELOPER LANDSCAPE
6.1. Chapter Overview
6.2. 3D Cell Culture System Developers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by 3D Cell Culture Format
6.2.5. Analysis by Type of Product
6.2.6. Analysis by 3D Cell Culture Format and Location of Headquarters
6.2.7. Analysis by Company Size and Type of Product
6.2.8. Analysis by Location of Headquarters
6.3. 3D Cell Cultures: List of Service Providers
6.4. 3D Cell Cultures: List of Affiliated Assays, Kits and Reagents
7. MARKET LANDSCAPE: SCAFFOLD BASED PRODUCTS
7.1. Chapter Overview
7.2. Scaffold Based Products: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Product
7.2.3. Analysis by Source of Scaffold
7.2.4. Analysis by Material Used for Fabrication
7.2.5. Analysis by Type of Product and Source of Scaffold
7.2.6. Analysis by Type of Product and Material Used for Fabrication
7.3. Scaffold Based Products: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Company Size and Type of Product
7.3.4. Analysis by Location of Headquarters
7.3.5. Leading Developers: Analysis by Number of Scaffold Based Products
8. MARKET LANDSCAPE: SCAFFOLD FREE PRODUCTS
8.1. Chapter Overview
8.2. Scaffold Free Products: Overall Market Landscape
8.2.1. Analysis by Status of Development
8.2.2. Analysis by Type of Product
8.2.3. Analysis by Material Used for Fabrication
8.2.4. Analysis by Material Used for Scaffold
8.2.5. Analysis by Type of Product and Material Used for Fabrication
8.3. Scaffold Free Products: Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Company Size and Type of Product
8.3.4. Analysis by Location of Headquarters
8.3.5. Leading Developers: Analysis by Number of Scaffold Free Products
9. MARKET LANDSCAPE: 3D BIOREACTORS
9.1. Chapter Overview
9.2. 3D Bioreactors: Overall Market Landscape
9.2.1. Analysis by Type of 3D Bioreactor
9.2.2. Analysis by Status of Development
9.2.3. Analysis by Working Volume
9.2.4. Analysis by Scale of Operation
9.2.5. Analysis by Manufacturing Process
9.2.6. Analysis by Type of Cell Culture System
9.2.7. Analysis by Type of Molecule Processed
9.2.8. Analysis by Area of Application
9.3. 3D Bioreactors: Developer Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Leading Developers: Analysis by Number of 3D Bioreactors
10. KEY APPLICATION AREAS
10.1. Chapter Overview
10.2. 3D Cell Culture Systems in Cancer Research
10.2.1. Need for 3D Culture Systems in Cancer Research
10.2.1.1. Cancer Drug Screening with 3D Culture Systems
10.3. 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
10.3.1. Drug Development Studies
10.3.2. Toxicity Screening
10.3.2.1. 3D Liver Models
10.3.2.2. Other 3D Models
10.4. 3D Cell Culture Systems in Stem Cell Research
10.4.1. 3D Culture Systems in Stem Cell Differentiation
10.4.2. In Vitro 3D Microenvironment to Induce Embryoid Body Formation
10.5. 3D Cell Cultures in Regenerative Medicine and Tissue Engineering
10.6. 3D Cell Culture Systems: Analysis by Key Application Areas
10.6.1. 3D Cell Culture Systems: Analysis by Key Application Areas and 3D Cell Culture Format
10.6.1.1. Scaffold Based 3D Products: Analysis by Key Application Areas
10.6.1.2. Scaffold Free 3D Products: Analysis by Key Application Areas
10.6.1.3. 3D Bioreactors: Analysis by Key Application Areas
11. COMPANY PROFILES: SCAFFOLD BASED PRODUCTS (HYDROGEL / ECM DEVELOPERS)
11.1. Chapter Overview
11.1.1. 3D Biotek
11.1.1.1. Company Overview
11.1.1.2. Product Portfolio
11.1.1.3. Recent Developments and Future Outlook
11.1.2. Advanced BioMatrix
11.1.2.1. Company Overview
11.1.2.2. Product Portfolio
11.1.2.3. Recent Development and Future Outlook
11.1.3. Alphabioregen
11.1.3.1. Company Overview
11.1.3.2. Product Portfolio
11.1.3.3. Recent Developments and Future Outlook
11.1.4. Corning Life Sciences
11.1.4.1. Company Overview
11.1.4.2. Product Portfolio
11.1.4.3. Recent Developments and Future Outlook
11.1.5. REPROCELL
11.1.5.1. Company Overview
11.1.5.2. Product Portfolio
11.1.5.3. Recent Developments and Future Outlook
12. COMPANY PROFILES: SCAFFOLD FREE PRODUCTS (ORGAN-ON-CHIPS DEVELOPERS)
12.1. Chapter Overview
12.1.1. CN Bio Innovations
12.1.1.1. Company Overview
12.1.1.2. Financial Information
12.1.1.3. Product Portfolio
12.1.1.4. Recent Developments and Future Outlook
12.1.2. Emulate
12.1.2.1. Company Overview
12.1.2.2. Financial Information
12.1.2.3. Product Portfolio
12.1.2.4. Recent Developments and Future Outlook
12.1.3. InSphero
12.1.3.1. Company Overview
12.1.3.2. Financial Information
12.1.3.3. Product Portfolio
12.1.3.4. Recent Developments and Future Outlook
12.1.4. MIMETAS
12.1.4.1. Company Overview
12.1.4.2. Financial Information
12.1.4.3. Product Portfolio
12.1.4.4. Recent Developments and Future Outlook
12.1.5. TissUse
12.1.5.1. Company Overview
12.1.5.2. Product Portfolio
12.1.5.3. Recent Developments and Future Outlook
13. COMPANY PROFILES: 3D BIOREACTORS
13.1. Chapter Overview
13.2. BISS TGT
13.2.1. Company Overview
13.2.2. Product Portfolio
13.2.3. Recent Developments and Future Outlook
13.3. Celartia
13.3.1. Company Overview
13.3.2. Product Portfolio
13.3.3. Recent Developments and Future Outlook
13.4. Cell Culture
13.4.1. Company Overview
13.4.2. Product Portfolio
13.4.3. Recent Developments and Future Outlook
13.5. EBERS
13.5.1. Company Overview
13.5.2. Product Portfolio
13.5.3. Recent Developments and Future Outlook
13.6. Flexcell International
13.6.1. Company Overview
13.6.2. Product Portfolio
13.6.3. Recent Developments and Future Outlook
13.7. PBS Biotech
13.7.1. Company Overview
13.7.2. Product Portfolio
13.7.3. Recent Developments and Future Outlook
13.8. Synthecon
13.8.1. Company Overview
13.8.2. Product Portfolio
13.8.3. Recent Developments and Future Outlook
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. 3D Cell Culture Systems: Funding and Investment Analysis
14.3.1. Analysis by Number of Funding Instances
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by 3D Cell Culture Format
14.3.5. Analysis by Type of Product
14.3.6. Analysis by Geography
14.3.7. Most Active Players: Analysis by Number of Funding Instances
14.3.8. Most Active Players: Analysis by Amount of Funding
14.3.9. Most Active Investors: Analysis by Number of Instances
14.4 Summary of Funding and Investments
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. 3D Cell Culture Systems: List of Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.2.1. Analysis by Year of Partnership and Type of Partnership
15.3.2.2. Analysis by Company Size and Type of Partnership
15.3.3. Analysis by Type of Partner
15.3.3.1. Analysis by Year of Partnership and Type of Partner
15.3.3.2. Analysis by Type of Partnership and Type of Partner
15.3.4. Analysis by 3D Cell Culture Format
15.3.4.1. Analysis by Year of Partnership and 3D Cell Culture Format
15.3.4.2. Analysis by Type of Partnership and 3D Cell Culture Format
15.3.5. Analysis by Type of Product
15.3.5.1. Analysis by Year of Partnership and Type of Product
15.3.5.2. Analysis by Type of Partnership and Type of Product
15.3.6. Most Active Players: Analysis by Number of Partnerships
15.3.7. Regional Analysis
15.3.8. Intercontinental and Intracontinental Agreements
16. PATENT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. 3D Cell Culture Systems: Patent Analysis
16.3.1. Analysis by Type of Patent
16.3.2. Analysis by Publication Year
16.3.3. Analysis by Type of Patent and Publication Year
16.3.3. Analysis by Issuing Authority
16.3.4. Analysis by CPC Symbols
16.3.5. Analysis by Type of Applicant
16.3.6. Word Cloud Analysis: Emerging Focus Areas
16.3.7. Leading Industry Players: Analysis by Number of Patents
16.3.8. Leading Non-Industry Players: Analysis by Number of Patents
16.4. 3D Cell Culture Systems: Patent Valuation Analysis
16.5. Leading Patents: Analysis by Number of Citations
17. PUBLICATION ANALYSIS
17.1. 3D Cell Culture Systems: Publication Analysis
17.2. Assumptions and Key Parameters
17.3. Methodology
17.3.1. Analysis by Year of Publication
17.3.2. Word Cloud Analysis: Emerging Focus Areas
17.3.3. Top Authors: Analysis by Number of Publications
17.3.4. Key Journals: Analysis by Number of Publications
17.3.5. Key Publishers: Analysis by Number of Publications
17.3.6. Leading Funding Institutes: Analysis by Number of Publications
18. PRODUCT COMPETITIVENESS ANALYSIS
18.1. Chapter Overview
18.2. Assumptions / Key Parameters
18.3. Methodology
18.4. Product Competitiveness Analysis: 3D Bioreactors
18.4.1. Companies Headquartered in North America
18.4.2. Companies Headquartered in Europe
18.4.3. Companies Headquartered in Asia-Pacific and Rest of the World
19. CASE STUDY: ORGANIDS AND ORGAN-ON-CHIPS
19.1. Chapter Overview
19.2. Organoids and Organ-on-Chips: List of Products
19.2.1. Analysis by Status of Development
19.2.2. Analysis by Application Area
19.3. Organoids and Organ-on-Chips: List of Product Developers
19.3.1. Analysis by Year of Establishment
19.3.2. Analysis by Company Size
19.3.3. Analysis by Location of Headquarters
20. MARKET FORECAST
20.1. Chapter Overview
20.2. Key Assumptions and Forecast Methodology
20.3. Global 3D Cell Culture Market, 2022-2035
20.4. Global 3D Cell Culture Market: Distribution by Business Segment
20.4.1. 3D Cell Culture Systems Market, 2022-2035
20.4.2. 3D Cell Culture Consumables Market, 2022-2035
20.4.3. 3D Cell Culture Services Market, 2022-2035
20.5. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format
20.5.1. 3D Cell Culture Systems Market for Scaffold Based Products, 2022-2035
20.5.2. 3D Cell Culture Systems Market for Scaffold Free Products, 2022-2035
20.5.3. 3D Cell Culture Systems Market for 3D Bioreactors, 2022-2035
20.6. Global 3D Cell Culture Systems Market: Distribution by Type of Product
20.6.1. 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2022-2035
20.6.2. 3D Cell Culture Systems Market for Hydrogels / ECMs, 2022-2035
20.6.3 3D Cell Culture Systems Market for Micropatterned Surface, 2022-2035
20.6.4. 3D Cell Culture Systems Market for Microcarriers, 2022-2035
20.6.5. 3D Cell Culture Systems Market for Microfluidic Systems, 2022-2035
20.6.6. 3D Cell Culture Systems Market for Solid Scaffolds, 2022-2035
20.6.7. 3D Cell Culture Systems Market for Suspension Culture Systems, 2022-2035
20.7. Global 3D Cell Culture Systems Market: Distribution by Area of Application
20.7.1. 3D Cell Culture Systems Market for Cancer Research, 2022-2035
20.7.2 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2022-2035
20.7.3. 3D Cell Culture Systems Market for Stem Cell Research, 2022-2035
20.7.4. 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2022-2035
20.8. Global 3D Cell Culture Systems Market: Distribution by Purpose
20.8.1. 3D Cell Culture Systems Market for Research Use, 2022-2035
20.8.2 3D Cell Culture Systems Market for Therapeutic Use, 2022-2035
20.9. Global 3D Cell Culture Systems Market: Distribution by Geography
20.9.1. 3D Cell Culture Systems Market in North America, 2022-2035
20.9.2 3D Cell Culture Systems Market in Europe, 2022-2035
20.9.3. 3D Cell Culture Systems Market in Asia-Pacific, 2022-2035
20.9.4. 3D Cell Culture Systems Market in Latin America, 2022-2035
20.9.5. 3D Cell Culture Systems Market in Middle East and North Africa, 2022-2035
20.9.6. 3D Cell Culture Systems Market in Rest of the World, 2022-2035
21. SURVEY ANALYSIS
21.1. Chapter Overview
21.2. Overview of Respondents
21.2.1. Designation of Respondents
21.3. Survey Insights
21.3.1. 3D Cell Culture Format
21.3.2. Type of Product(s) Offered
21.3.3. Status of Development of Product(s)
21.3.4. Source of 3D Cultured Cells
21.3.5. Method Used for Fabrication
21.3.6. Area(s) of Application
21.3.7. Services Offered for 3D Cell Cultures
21.3.8. Current and Future Market Opportunity
22. CONCLUSION
23. EXECUTIVE INSIGHTS
23.1. Chapter Overview
23.2. Cellendes
23.2.1. Company Snapshot
23.2.2. Interview Transcript: Brigitte Angres, Co-founder
23.3. Synthecon
23.3.1. Company Snapshot
23.3.2. Interview Transcript: Bill Anderson, President and Chief Executive Officer
23.4. Anonymous
23.4.1. Interview Transcript: Anonymous, President and Chief Executive Officer
23.5. Anonymous
23.5.1. Interview Transcript: Anonymous, Co-founder and Vice President
23.6. BRTI Life Sciences
23.6.1. Company Snapshot
22.6.2. Interview Transcript: Scott Brush, Vice President
23.7. Kirkstall
23.7.1. Company Snapshot
23.7.2. Interview Transcript: Malcolm Wilkinson, Non-Executive Director
23.8. QGel
23.8.1. Company Snapshot
23.8.2. Interview Transcript: Ryder Clifford, Chief Executive Officer and Simone Carlo Rizzi, Chief Scientific Officer
23.9. Xylyx Bio
23.9.1. Company Snapshot
23.9.2. Interview Transcript: Tanya Yankelevich, Former Director of Product Management and Business Development
23.10. InSphero
23.10.1. Company Snapshot
23.10.2. Interview Transcript: Jens Kelm, Former Chief Scientific Officer
23.11. GSI
23.11.1. Company Snapshot
23.11.2. Interview Transcript: Walter Tinganelli, Group Leader, Clinical Radiobiology
23.12. Nanofiber Solutions
23.12.1. Company Snapshot
23.12.2. Interview Transcript: Darlene Thieken, Former Project Manager
23.13. FlexCell International
23.13.1. Company Snapshot
23.13.2. Interview Transcript: Andrea Picon, Director of Business Development
23.14. InSphero
23.14.1. Company Snapshot
23.14.2. Interview Transcript: Frank Junker, Chief Business officer
23.15. MBL International
23.15.1. Company Snapshot
23.15.2. Interview Transcript: Mamun, Rahman, Manger, Business Development
24. APPENDIX I: TABULATED DATA
25. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Cell Cultures
3.2.1. Primary Cell Cultures
3.2.2. Cell Lines
3.3. Morphology of Cells in Culture
3.4. 2D Cell Cultures vs 3D Cell Cultures
3.5. Overview of 3D Cell Culturing
3.5.1. Components of the Extracellular Matrix (ECM)
3.5.2. In Vitro Cell Culturing
3.5.3. Selection of Culture Format
3.6. Establishment and Maintenance of Cell Cultures
3.6.1. Isolating Cells from Tissues
3.6.2. Maintaining Cells in Culture
3.6.3. Sub-Culturing / Passaging
3.6.4. Cryogenic Storage
3.7. Requirements for Maintaining Healthy Cell Cultures
3.7.1. Safety Guidelines in a Cell Culture Facility
3.7.2. Cell Culture Health and Optimal Conditions for Growth
3.7.3. Cross Contamination in Cell Cultures
3.7.4. Methods to Prevent Contamination
3.8. Applications of 3D Cell Culture Systems
3.8.1. Model Systems
3.8.2. Drug Discovery and Preclinical Research
3.8.3. Cancer Research
3.8.4. Virology Research
3.8.5. Genetic Engineering and Gene Therapy Research
3.9. Advantages and Limitations of 3D Cell Culture Systems
3.10. Future Perspectives
4. CLASSIFICATION OF 3D CELL CULTURE SYSTEMS
4.1. 3D Cell Culture Classification
4.2. Scaffold Based 3D Cell Cultures
4.2.1. Hydrogels / ECM Analogs
4.2.2. Solid Scaffolds
4.2.3. Micropatterned Surfaces
4.2.4. Microcarriers
4.3. Scaffold Free 3D Cell Cultures
4.3.1. Attachment Resistant Surfaces
4.3.2. Suspension Culture Systems
4.3.2.1. Hanging Drop Plates
4.3.2.2. Magnetic Levitation and 3D Bioprinting
4.3.3. Microfluidic Surfaces and Organs-on-Chips
4.3.4. 3D Bioreactors
4.4. Organoids
5. FABRICATION OF 3D MATRICES AND SCAFFOLDS
5.1. Chapter Overview
5.2. Methods for Fabricating Porous Scaffolds
5.2.1. Particulate Leaching
5.2.2. Solvent Casting
5.2.3. Emulsion Templating
5.2.4. Gas Foaming
5.2.5. Melt Molding
5.2.6. Microsphere Sintering
5.3. Methods for Fabricating Fibrous Scaffolds
5.3.1. Electrospinning
5.3.2. Phase Separation
5.3.3. Self-Assembly
5.3.4. Fiber Mesh and Fiber Bonding
5.4. Methods for Fabricating Hydrogels
5.4.1. Gelation
5.4.2. Solvent Casting and Particulate Leaching
5.4.3. Gas Foaming
5.4.4. Freeze Drying
5.4.5. Co-polymerization / Crosslinking
5.4.6. Microfluidics
5.5. Methods for Fabricating Custom Scaffolds
5.5.1. Stereo-Lithography
5.5.2. 3D Bioprinting and Selective Laser Sintering (SLS)
5.5.3. Fused Deposition Modeling
5.5.4. Membrane Lamination
5.5.5. Rapid Prototyping / Solid Free-Form Technique
5.6. Methods for Fabricating Microspheres
5.6.1. Solvent Evaporation
5.6.2. Single and Double Emulsification
5.6.3. Particle Aggregation
5.7. Methods for Fabricating Native Scaffolds
5.7.1. Decellularization
6. 3D CELL CULTURE SYSTEMS: DEVELOPER LANDSCAPE
6.1. Chapter Overview
6.2. 3D Cell Culture System Developers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by 3D Cell Culture Format
6.2.5. Analysis by Type of Product
6.2.6. Analysis by 3D Cell Culture Format and Location of Headquarters
6.2.7. Analysis by Company Size and Type of Product
6.2.8. Analysis by Location of Headquarters
6.3. 3D Cell Cultures: List of Service Providers
6.4. 3D Cell Cultures: List of Affiliated Assays, Kits and Reagents
7. MARKET LANDSCAPE: SCAFFOLD BASED PRODUCTS
7.1. Chapter Overview
7.2. Scaffold Based Products: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Product
7.2.3. Analysis by Source of Scaffold
7.2.4. Analysis by Material Used for Fabrication
7.2.5. Analysis by Type of Product and Source of Scaffold
7.2.6. Analysis by Type of Product and Material Used for Fabrication
7.3. Scaffold Based Products: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Company Size and Type of Product
7.3.4. Analysis by Location of Headquarters
7.3.5. Leading Developers: Analysis by Number of Scaffold Based Products
8. MARKET LANDSCAPE: SCAFFOLD FREE PRODUCTS
8.1. Chapter Overview
8.2. Scaffold Free Products: Overall Market Landscape
8.2.1. Analysis by Status of Development
8.2.2. Analysis by Type of Product
8.2.3. Analysis by Material Used for Fabrication
8.2.4. Analysis by Material Used for Scaffold
8.2.5. Analysis by Type of Product and Material Used for Fabrication
8.3. Scaffold Free Products: Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Company Size and Type of Product
8.3.4. Analysis by Location of Headquarters
8.3.5. Leading Developers: Analysis by Number of Scaffold Free Products
9. MARKET LANDSCAPE: 3D BIOREACTORS
9.1. Chapter Overview
9.2. 3D Bioreactors: Overall Market Landscape
9.2.1. Analysis by Type of 3D Bioreactor
9.2.2. Analysis by Status of Development
9.2.3. Analysis by Working Volume
9.2.4. Analysis by Scale of Operation
9.2.5. Analysis by Manufacturing Process
9.2.6. Analysis by Type of Cell Culture System
9.2.7. Analysis by Type of Molecule Processed
9.2.8. Analysis by Area of Application
9.3. 3D Bioreactors: Developer Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Leading Developers: Analysis by Number of 3D Bioreactors
10. KEY APPLICATION AREAS
10.1. Chapter Overview
10.2. 3D Cell Culture Systems in Cancer Research
10.2.1. Need for 3D Culture Systems in Cancer Research
10.2.1.1. Cancer Drug Screening with 3D Culture Systems
10.3. 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
10.3.1. Drug Development Studies
10.3.2. Toxicity Screening
10.3.2.1. 3D Liver Models
10.3.2.2. Other 3D Models
10.4. 3D Cell Culture Systems in Stem Cell Research
10.4.1. 3D Culture Systems in Stem Cell Differentiation
10.4.2. In Vitro 3D Microenvironment to Induce Embryoid Body Formation
10.5. 3D Cell Cultures in Regenerative Medicine and Tissue Engineering
10.6. 3D Cell Culture Systems: Analysis by Key Application Areas
10.6.1. 3D Cell Culture Systems: Analysis by Key Application Areas and 3D Cell Culture Format
10.6.1.1. Scaffold Based 3D Products: Analysis by Key Application Areas
10.6.1.2. Scaffold Free 3D Products: Analysis by Key Application Areas
10.6.1.3. 3D Bioreactors: Analysis by Key Application Areas
11. COMPANY PROFILES: SCAFFOLD BASED PRODUCTS (HYDROGEL / ECM DEVELOPERS)
11.1. Chapter Overview
11.1.1. 3D Biotek
11.1.1.1. Company Overview
11.1.1.2. Product Portfolio
11.1.1.3. Recent Developments and Future Outlook
11.1.2. Advanced BioMatrix
11.1.2.1. Company Overview
11.1.2.2. Product Portfolio
11.1.2.3. Recent Development and Future Outlook
11.1.3. Alphabioregen
11.1.3.1. Company Overview
11.1.3.2. Product Portfolio
11.1.3.3. Recent Developments and Future Outlook
11.1.4. Corning Life Sciences
11.1.4.1. Company Overview
11.1.4.2. Product Portfolio
11.1.4.3. Recent Developments and Future Outlook
11.1.5. REPROCELL
11.1.5.1. Company Overview
11.1.5.2. Product Portfolio
11.1.5.3. Recent Developments and Future Outlook
12. COMPANY PROFILES: SCAFFOLD FREE PRODUCTS (ORGAN-ON-CHIPS DEVELOPERS)
12.1. Chapter Overview
12.1.1. CN Bio Innovations
12.1.1.1. Company Overview
12.1.1.2. Financial Information
12.1.1.3. Product Portfolio
12.1.1.4. Recent Developments and Future Outlook
12.1.2. Emulate
12.1.2.1. Company Overview
12.1.2.2. Financial Information
12.1.2.3. Product Portfolio
12.1.2.4. Recent Developments and Future Outlook
12.1.3. InSphero
12.1.3.1. Company Overview
12.1.3.2. Financial Information
12.1.3.3. Product Portfolio
12.1.3.4. Recent Developments and Future Outlook
12.1.4. MIMETAS
12.1.4.1. Company Overview
12.1.4.2. Financial Information
12.1.4.3. Product Portfolio
12.1.4.4. Recent Developments and Future Outlook
12.1.5. TissUse
12.1.5.1. Company Overview
12.1.5.2. Product Portfolio
12.1.5.3. Recent Developments and Future Outlook
13. COMPANY PROFILES: 3D BIOREACTORS
13.1. Chapter Overview
13.2. BISS TGT
13.2.1. Company Overview
13.2.2. Product Portfolio
13.2.3. Recent Developments and Future Outlook
13.3. Celartia
13.3.1. Company Overview
13.3.2. Product Portfolio
13.3.3. Recent Developments and Future Outlook
13.4. Cell Culture
13.4.1. Company Overview
13.4.2. Product Portfolio
13.4.3. Recent Developments and Future Outlook
13.5. EBERS
13.5.1. Company Overview
13.5.2. Product Portfolio
13.5.3. Recent Developments and Future Outlook
13.6. Flexcell International
13.6.1. Company Overview
13.6.2. Product Portfolio
13.6.3. Recent Developments and Future Outlook
13.7. PBS Biotech
13.7.1. Company Overview
13.7.2. Product Portfolio
13.7.3. Recent Developments and Future Outlook
13.8. Synthecon
13.8.1. Company Overview
13.8.2. Product Portfolio
13.8.3. Recent Developments and Future Outlook
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. 3D Cell Culture Systems: Funding and Investment Analysis
14.3.1. Analysis by Number of Funding Instances
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by 3D Cell Culture Format
14.3.5. Analysis by Type of Product
14.3.6. Analysis by Geography
14.3.7. Most Active Players: Analysis by Number of Funding Instances
14.3.8. Most Active Players: Analysis by Amount of Funding
14.3.9. Most Active Investors: Analysis by Number of Instances
14.4 Summary of Funding and Investments
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. 3D Cell Culture Systems: List of Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.2.1. Analysis by Year of Partnership and Type of Partnership
15.3.2.2. Analysis by Company Size and Type of Partnership
15.3.3. Analysis by Type of Partner
15.3.3.1. Analysis by Year of Partnership and Type of Partner
15.3.3.2. Analysis by Type of Partnership and Type of Partner
15.3.4. Analysis by 3D Cell Culture Format
15.3.4.1. Analysis by Year of Partnership and 3D Cell Culture Format
15.3.4.2. Analysis by Type of Partnership and 3D Cell Culture Format
15.3.5. Analysis by Type of Product
15.3.5.1. Analysis by Year of Partnership and Type of Product
15.3.5.2. Analysis by Type of Partnership and Type of Product
15.3.6. Most Active Players: Analysis by Number of Partnerships
15.3.7. Regional Analysis
15.3.8. Intercontinental and Intracontinental Agreements
16. PATENT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. 3D Cell Culture Systems: Patent Analysis
16.3.1. Analysis by Type of Patent
16.3.2. Analysis by Publication Year
16.3.3. Analysis by Type of Patent and Publication Year
16.3.3. Analysis by Issuing Authority
16.3.4. Analysis by CPC Symbols
16.3.5. Analysis by Type of Applicant
16.3.6. Word Cloud Analysis: Emerging Focus Areas
16.3.7. Leading Industry Players: Analysis by Number of Patents
16.3.8. Leading Non-Industry Players: Analysis by Number of Patents
16.4. 3D Cell Culture Systems: Patent Valuation Analysis
16.5. Leading Patents: Analysis by Number of Citations
17. PUBLICATION ANALYSIS
17.1. 3D Cell Culture Systems: Publication Analysis
17.2. Assumptions and Key Parameters
17.3. Methodology
17.3.1. Analysis by Year of Publication
17.3.2. Word Cloud Analysis: Emerging Focus Areas
17.3.3. Top Authors: Analysis by Number of Publications
17.3.4. Key Journals: Analysis by Number of Publications
17.3.5. Key Publishers: Analysis by Number of Publications
17.3.6. Leading Funding Institutes: Analysis by Number of Publications
18. PRODUCT COMPETITIVENESS ANALYSIS
18.1. Chapter Overview
18.2. Assumptions / Key Parameters
18.3. Methodology
18.4. Product Competitiveness Analysis: 3D Bioreactors
18.4.1. Companies Headquartered in North America
18.4.2. Companies Headquartered in Europe
18.4.3. Companies Headquartered in Asia-Pacific and Rest of the World
19. CASE STUDY: ORGANIDS AND ORGAN-ON-CHIPS
19.1. Chapter Overview
19.2. Organoids and Organ-on-Chips: List of Products
19.2.1. Analysis by Status of Development
19.2.2. Analysis by Application Area
19.3. Organoids and Organ-on-Chips: List of Product Developers
19.3.1. Analysis by Year of Establishment
19.3.2. Analysis by Company Size
19.3.3. Analysis by Location of Headquarters
20. MARKET FORECAST
20.1. Chapter Overview
20.2. Key Assumptions and Forecast Methodology
20.3. Global 3D Cell Culture Market, 2022-2035
20.4. Global 3D Cell Culture Market: Distribution by Business Segment
20.4.1. 3D Cell Culture Systems Market, 2022-2035
20.4.2. 3D Cell Culture Consumables Market, 2022-2035
20.4.3. 3D Cell Culture Services Market, 2022-2035
20.5. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format
20.5.1. 3D Cell Culture Systems Market for Scaffold Based Products, 2022-2035
20.5.2. 3D Cell Culture Systems Market for Scaffold Free Products, 2022-2035
20.5.3. 3D Cell Culture Systems Market for 3D Bioreactors, 2022-2035
20.6. Global 3D Cell Culture Systems Market: Distribution by Type of Product
20.6.1. 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2022-2035
20.6.2. 3D Cell Culture Systems Market for Hydrogels / ECMs, 2022-2035
20.6.3 3D Cell Culture Systems Market for Micropatterned Surface, 2022-2035
20.6.4. 3D Cell Culture Systems Market for Microcarriers, 2022-2035
20.6.5. 3D Cell Culture Systems Market for Microfluidic Systems, 2022-2035
20.6.6. 3D Cell Culture Systems Market for Solid Scaffolds, 2022-2035
20.6.7. 3D Cell Culture Systems Market for Suspension Culture Systems, 2022-2035
20.7. Global 3D Cell Culture Systems Market: Distribution by Area of Application
20.7.1. 3D Cell Culture Systems Market for Cancer Research, 2022-2035
20.7.2 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2022-2035
20.7.3. 3D Cell Culture Systems Market for Stem Cell Research, 2022-2035
20.7.4. 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2022-2035
20.8. Global 3D Cell Culture Systems Market: Distribution by Purpose
20.8.1. 3D Cell Culture Systems Market for Research Use, 2022-2035
20.8.2 3D Cell Culture Systems Market for Therapeutic Use, 2022-2035
20.9. Global 3D Cell Culture Systems Market: Distribution by Geography
20.9.1. 3D Cell Culture Systems Market in North America, 2022-2035
20.9.2 3D Cell Culture Systems Market in Europe, 2022-2035
20.9.3. 3D Cell Culture Systems Market in Asia-Pacific, 2022-2035
20.9.4. 3D Cell Culture Systems Market in Latin America, 2022-2035
20.9.5. 3D Cell Culture Systems Market in Middle East and North Africa, 2022-2035
20.9.6. 3D Cell Culture Systems Market in Rest of the World, 2022-2035
21. SURVEY ANALYSIS
21.1. Chapter Overview
21.2. Overview of Respondents
21.2.1. Designation of Respondents
21.3. Survey Insights
21.3.1. 3D Cell Culture Format
21.3.2. Type of Product(s) Offered
21.3.3. Status of Development of Product(s)
21.3.4. Source of 3D Cultured Cells
21.3.5. Method Used for Fabrication
21.3.6. Area(s) of Application
21.3.7. Services Offered for 3D Cell Cultures
21.3.8. Current and Future Market Opportunity
22. CONCLUSION
23. EXECUTIVE INSIGHTS
23.1. Chapter Overview
23.2. Cellendes
23.2.1. Company Snapshot
23.2.2. Interview Transcript: Brigitte Angres, Co-founder
23.3. Synthecon
23.3.1. Company Snapshot
23.3.2. Interview Transcript: Bill Anderson, President and Chief Executive Officer
23.4. Anonymous
23.4.1. Interview Transcript: Anonymous, President and Chief Executive Officer
23.5. Anonymous
23.5.1. Interview Transcript: Anonymous, Co-founder and Vice President
23.6. BRTI Life Sciences
23.6.1. Company Snapshot
22.6.2. Interview Transcript: Scott Brush, Vice President
23.7. Kirkstall
23.7.1. Company Snapshot
23.7.2. Interview Transcript: Malcolm Wilkinson, Non-Executive Director
23.8. QGel
23.8.1. Company Snapshot
23.8.2. Interview Transcript: Ryder Clifford, Chief Executive Officer and Simone Carlo Rizzi, Chief Scientific Officer
23.9. Xylyx Bio
23.9.1. Company Snapshot
23.9.2. Interview Transcript: Tanya Yankelevich, Former Director of Product Management and Business Development
23.10. InSphero
23.10.1. Company Snapshot
23.10.2. Interview Transcript: Jens Kelm, Former Chief Scientific Officer
23.11. GSI
23.11.1. Company Snapshot
23.11.2. Interview Transcript: Walter Tinganelli, Group Leader, Clinical Radiobiology
23.12. Nanofiber Solutions
23.12.1. Company Snapshot
23.12.2. Interview Transcript: Darlene Thieken, Former Project Manager
23.13. FlexCell International
23.13.1. Company Snapshot
23.13.2. Interview Transcript: Andrea Picon, Director of Business Development
23.14. InSphero
23.14.1. Company Snapshot
23.14.2. Interview Transcript: Frank Junker, Chief Business officer
23.15. MBL International
23.15.1. Company Snapshot
23.15.2. Interview Transcript: Mamun, Rahman, Manger, Business Development
24. APPENDIX I: TABULATED DATA
25. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
